The company specializes in developing human antibody products for cancer treatment, with Pritimumab achieving FDA orphan drug status for addressing rare forms of cancer. NBIO's clinical premise is to modulate the human body's natural immune response using monoclonal antibodies and cytokines that can be combined to maximize therapeutic effectiveness.
Cyborg Score Rationale
In January 2025, the company received notification of failure to file its Form 10-Q timely, resulting in its stock being moved to OTC Markets' 'Expert Market' and no longer quoted on regular platforms. The company faces significant reporting and operational challenges despite having a validated lead program in Phase 2 clinical trials.
Top Insights
Lead candidate Pritumumab in Phase 2 clinical trials for brain cancer treatment
FDA orphan drug designation for Pritimumab signals regulatory recognition of clinical need in rare cancers
As of January 2025, company delisted from regular OTC quotation due to delayed SEC filings
MultiPharm proprietary platform targeting applications beyond oncology including diabetes, autoimmunity, and transplantation
Named Competitors
Opdivo — Anti-PD-1 monoclonal antibody for multiple cancer indications
Keytruda — PD-1 inhibitor immunotherapy for various cancer types
Tecentriq — PD-L1 targeted monoclonal antibody for cancer treatment
Recent Developments
(January 2025) Failed to file quarterly report timely; stock moved to OTC Expert Market
(December 2025) Company noted 18-month challenging period for shareholders
(2024) Phase 2 clinical trials ongoing for Pritumumab in brain cancer
Open the full interactive Nascent Biotech Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.